At the Thombosis & Hemostasis Research Unit we employ advanced analyses of platetelet function, thrombin generation, clot formation and fibrinolysis. We focus on thrombosis and/or bleeding risk in cancer patients, critically ill patients and patients undergoing cardiac surgery.

Our research focus on cancer screening programmes. This includes effectiveness studies, citizens perspective, how to reduce barriers and increase informed participation, provide equal access for all populationgroups, and idevelop and refine screening diagnostics and derived clinical procedures.

We investigate the radiobiology of particle therapy, how this differs from radiation with conventional radiotherapy, and how different modalities of particle therapy effect the radiation response. To do this we use a range of biological models from cell culture to animal systems.

Our research aim to optimize radiotherapy so more patients can be cured with less side effects. Understanding the biology, physical properties of ionizing beams (x-rays and protons), new delivery techniques, and testing of new treatments and concepts in the clinic. Special focus on proton therapy.

We investigate chromosomal and genomic aberrations in hematological malignant diseases, in which the majority of cases are fatal, using advanced molecular cytogenetics and bioinformatics. Our major goal is to transform our findings into improved prognosis and therapy for this disease group.

We conduct clinical epidemiological studies of late effects of cancer treatment in survivors of childhood and their offspring in national, Nordic and international settings, including molecular studies based on clinical data and biological specimens for genetic evaluations.

We pursue to individualise and optimise radiotherapy to patients with cancer in the head and neck region (HNSCC). Especially, biological characterisation of those tending to recur in the high-dose region and possible ways to avoid this. We also focus on individualised use of immunotherapy to HNSCC.

The focus of our research group is radiotherapy in cervix cancer. The group is actively involved in coordination of large international clinical studies (the EMBRACE studies: with the aim of continuously setting new international standards for radiotherapy in cervix cancer.

Our research focuses on prostate cancer and personalized medicine. We use e.g. next generation sequencing for molecular profiling of tumor, blood, and urine samples from patients. We also run clinical trials. The overall aim is to develop novel biomarkers and obtain new insights into tumor biology.

My research group investigates the role of the tumor vasculature and microenvironment on radiation response. Using tumors and normal tissues, our pre-clinical translational studies identify clinically applicable methods to monitor and modify these parameters, thus improving outcome to radiotherapy.

A main research area is motion management in both photon radiotherapy and proton therapy: How can tumor and organ motion during treatment delivery be monitored, how does it affect treatments, and how can its impact be mitigated. Other areas include radiobiology with a focus on proton FLASH therapy.

Cancer is an obesity-related comorbidity, and obesity impair cancer prognosis. Our ambition is to revert the impact of a “globese” world through multidisciplinary approaches. We aim to determine both biological and clinical mechanisms towards improved, personalized care for obese cancer patients.

We investigate use of computational methods in radiation oncology – artificial intelligence, big data, and high-performance computer simulations. We are particularly interested in image segmentation, for various of imaging modalities, and robust treatment planning for photon and proton radiotherapy.

Associate Professors

Our research focuses on cancer epidemiology. We incorporate molecular and genetic techniques in population-based research, and pharmacoepidemiologic studies to investigate cancer risk and prognosis. Most of our research is on breast cancer – encompassing etiology, treatment, prognosis, and survivorship.

Therapeutic drug monitoring (TDM) is the tool to improve patient outcomes and reduce healthcare costs. We investigate the role and need for monitorering of novel and classic TDM medicine (e.g. TKI) with chromatography based methods (LC-MSMS). TDM can bring personalized medicine into practice.

We focus on therapeutic drug monitoring by studying pharmaceuticals, drugs of abuse, and other foreign substances, such as artificial sweeteners, in various human fluids by mass spectrometry. We also investigate the whereabouts of vitamin B12 in health and disease.

Our research is focused on time-resolved dosimetry. The aim is to determine the dose delivered during radiotherapy. We have been developing detectors based on scintillators, which is tested for multiple modalities, e.g. a clinical study in brachytherapy and small animal studies in proton therapy.

For cancer treatment with radiotherapy and surgery it is important to know the location and shape of the tumour. We therefore need to define exactly what is tumour on medical images, such as CT, PET, and MRI. We investigate how we can improve the tumour definition on imaging for better treatments.

We investigate the correlation between advanced MRI sequences changes and cognitive decline following Proton and Photon therapy for brain cancer patients. We investigate advanced MRI technique to help improve definition of malignant regions through a priori knowledge of cell migration patterns.

Head and neck cancer is a life threatening disease and treatment often leads to severe side effects. At the Danish Center for Particle Therapy, we wish to explore this new modality; patient selection, treatment delivery, treatment of side effects, the lasting side effects as well as tumour control.

My research is focused on PET imaging in urologic and gynecologic cancers, tumor perfusion quantified with PET, radiation therapy induced cardiac and lung damage evaluated with PET in breast cancer and esophageal cancer patients, and cardiac perfusion PET in ischemic heart disease.

The main goal in our lab is to unravel biological chracteristics in hematological malignancies aiming at (i) improved diagnostic precision, (ii) determine patient prognosis more accurately, and (iii) to provide new markers for targeted therapy with the ultimate aim of improving patient survival.

Focus is on the use of biomarkers in hematology and allergy. E.g. leukocyt and bacteria count in body fluids for faster diagnoses. Projects are also ongoing in the area of "preanalysis". E.g. investigation of the relation between G forces and hemolysis in pneumatic tube transport of blood samples.

Our lab utilizes cancer NGS data and computational tools to understand cancer evolution and to describe the temporal order of mutations. With blood-based biomarkers like ctDNA, we can track cancer evolution in vivo during and after treatment to ultimately build tools that may improve patient outcome.

My group uses statistical and computational approaches to study questions in human genomics. One focus is mutation processes in somatic and germline cells, including the rate, pattern, and effects of new mutations. Another focus is the development of machine learning methods for precision medicine.

Our research group study benefits and harms of breast, colorectal and cervical cancer screening. Our aim is to bring forward precise estimates of the benefits and harms of cancer screening and to improve cancer screening programmes through studies on how to individualize cancer screening and improve follow-up after cancer screening.

My translational research is anchored in a multidisciplinary teamwork and developed in a patient-centered, clinical setting. We focus on 1) indications for radiotherapy in breast and head/neck cancer and 2) phenotypical appearances of precursor lesions in the breast (incl. DCIS and apocrine lesions).

Assistant Professors and Postdocs

Early detection of prostate cancer is essential to survival, but not all cancers will give rise to symptoms if left untreated. Our research focuses on developing new and minimally invasive methods of early detecting and identifying aggressive prostate cancers, while curative treatment is available.

Our research focuses on improving and developing MR based methods for metabolic profiling of cells, biopsies and biofluids. We utilize the molecular imaging technique hyperpolarized 13C MR to create a better understanding of the biomolecular patterns related to disease progression and treatment.

The motivation of our research is to transcend hyperpolarized carbon-13 MRI from research community to clinic and thereby contribute greatly in perfusion and metabolic imaging. Hyperpolarized carbon-13 MRI serves as a contrast agent with dramatical increased signal compared to conventional MRI.